

Douillard, J. Y., Shepherd, F. A., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., ... & Kim, E. S. (2010). Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. *Journal of Clinical Oncology*, 28(5), 744-752.

Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., ... & Larson, R. A. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *New England Journal of Medicine*, 355(23), 2408-2417.

Duggan, K. C., Walters, M. J., Musee, J., Harp, J. M., Kiefer, J. R., Oates, J. A., & Marnett, L. J. (2010). Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. *Journal of Biological Chemistry*, 285(45), 34950-34959.

Dvorak, H. F. (2002). Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. *Journal of clinical oncology*, 20(21), 4368-4380.

Ebert, B. L., Galili, N., Tamayo, P., Bosco, J., Mak, R., Pretz, J., ... & Raza, A. (2008). An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. *PLoS medicine*, 5(2), e35.

Ellis, L. M., & Hicklin, D. J. (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. *Nature Reviews Cancer*, 8(8), 579-591.

Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007). Molecular basis for sunitinib efficacy and future clinical development. *Nature Reviews Drug Discovery*, 6(9), 734-745.